ZG006 not checked

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
11 active
11 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Small Cell Lung Cancer (5 trials), Neuroendocrine Carcinoma (4 trials), Small-cell Lung Cancer, Neuroendocrine Prostate Cancer, Neuroendocrine Cancer, Solid Tumor, Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Main trialPhase 3
“This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine carcinoma who have received prior systemic therapy.”In the company’s words, NCT07595913 on ClinicalTrials.gov

Other drugs for Small Cell Lung Cancer

All 118 drugs for Small Cell Lung Cancer

Coming up9

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Jun 2028 A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Phase 3Recruiting Oct 2028 Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Phase 2Not yet recruiting Dec 2027 Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
Phase 1/2Recruiting May 2026 Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Phase 1/2Recruiting Sep 2026 Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1/2Recruiting Apr 2027 Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Phase 1/2Recruiting Sep 2027 ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1/2Recruiting Dec 2028 Study of ZGGS34 in Participants With Advanced Solid Tumors
Phase 1Recruiting Dec 2026 A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
Phase 1Not yet recruiting 15 Sep 2028 A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
Phase 1Recruiting Dec 2028 Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ZG006

Following is part of Solo: you see every change to ZG006 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in